Traders should monitor warrant exercise activity by April 17, 2026, which could significantly extend cash runway and reduce near-term dilution risk. Upcoming clinical milestones — including OV329 Phase 2 initiation and OV4071 ketamine challenge data in mid-2026 — may drive sentiment, but current profitability is inflated by non-recurring gains.
Price Chart
Executive Summary
Ovid Therapeutics reported Q4 and full-year 2025 financial results, highlighted by a $9.7 million net income in Q4 driven by a $21 million gain on a long-term equity investment, despite ongoing R&D losses. The company advanced its pipeline with positive Phase 1 safety data for OV329 at 7 mg, expansion into TSC and infantile spasms, and regulatory clearance to begin a Phase 1 trial for its first-in-class oral KCC2 activator OV4071 in Australia. A $60 million private placement and potential $53.9 million from warrant exercises extend cash runway into late 2028 or possibly 2029.
Key Financial Metrics
Key Facts
- OV329 showed favorable safety and tolerability at 7 mg with no treatment-related adverse events; advancing to Phase 2 trials in focal onset seizures (Q2 2026) and proof-of-concept studies in TSC (Q4 2026) and infantile spasms (2027).
- OV4071 received HREC and TGA approval in Australia for Phase 1 trials, triggering a 30-day warrant exercise window; full exercise could bring $53.9 million in gross proceeds.
- Company raised $60 million via private placement and ended 2025 with $90.4 million in cash, funding operations into late 2028 (potentially 2029 with warrant proceeds).
- Q4 2025 net income was $9.7 million ($0.06/share), a turnaround from $9.3 million loss in Q4 2024, primarily due to a $21.0 million non-recurring gain on an equity investment.
- Full-year 2025 net loss was $17.4 million ($0.23/share), improved from $26.4 million loss in 2024, but core operations remain unprofitable.
Financial Impact
$60 million raised in private placement; up to $53.9 million more possible from warrant exercises; $21 million one-time gain boosted Q4 income
Risk Factors
- Q4 profitability was driven by a one-time $21 million gain; underlying operations remain loss-making.
- Warrant exercises are not guaranteed — if not exercised, future dilution or financing risk increases.
- Clinical development in epilepsy and KCC2 programs remains high-risk with no near-term revenue potential.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257984 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 10w ago | 144 | $2.89 | awaiting T+60 | — | $2.15 (−25.43%) |
Jul 8, 2026 15w ago | 8-K | $2.73 $2.49 | ▼ −8.79% | ▼ −11.10% | $2.15 (−21.06%) |
Jun 3, 2026 20w ago | 8-K | $2.39 $2.93 | ▲ +22.59% | ▲ +20.10% | $2.15 (−9.83%) |
May 12, 2026 24w ago | Press Release | $2.87 $2.65 | ▼ −7.67% | ▼ −12.05% | $2.15 (−24.91%) |
Apr 27, 2026 26w ago | EFFECT | $2.69 $2.38 | ▼ −11.52% | ▼ −16.30% | $2.15 (−19.89%) |
Apr 21, 2026 26w ago | S-3 | $2.66 $2.44 | ▼ −8.27% | ▼ −13.05% | $2.15 (−18.98%) |
Apr 20, 2026 27w ago | 8-K | $2.89 $2.49 | ▼ −13.84% | ▼ −20.62% | $2.15 (−25.43%) |
Mar 18, 2026 31w ago | 8-K | $2.30 $2.21 | ▼ −3.91% | ▼ −15.44% | $2.15 (−6.30%) |
Mar 18, 2026 31w ago | Press Release | $2.30 $2.21 | ▼ −3.91% | ▼ −15.44% | $2.15 (−6.30%) |
Mar 18, 2026 31w ago | Press Release | $2.30 $2.21 | ▼ −3.91% | ▼ −15.44% | $2.15 (−6.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers